Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults.

Aggarwal A, Schrimpf L, Lauriello J.

Clin Schizophr Relat Psychoses. 2018 Jan;11(4):221-223. doi: 10.3371/CSRP.AGSC.010318. Review.

PMID:
29341822
2.

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).

Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB.

Cochrane Database Syst Rev. 2018 Jan 8;1:CD008074. doi: 10.1002/14651858.CD008074.pub2. Review.

PMID:
29308601
3.

Aripiprazole-induced transient myopia: A rare entity.

Praveen Kumar KV, Chiranjeevi P, Alam MS.

Indian J Ophthalmol. 2018 Jan;66(1):130-131. doi: 10.4103/ijo.IJO_907_16.

4.

Aripiprazole Lauroxil: A Review in Schizophrenia.

Frampton JE.

Drugs. 2017 Dec;77(18):2049-2056. doi: 10.1007/s40265-017-0848-4. Review.

PMID:
29177572
5.

Urinary retention associated with aripiprazole: Report of a new case and review of the literature.

Boyer MG, Kheloufi F, Denis J, Micallef J, Milh M.

Therapie. 2018 May - Jun;73(3):287-289. doi: 10.1016/j.therap.2017.09.001. Epub 2017 Oct 23. No abstract available.

PMID:
29146041
6.

Late Reduction of Cocaine Cravings in a Randomized, Double-Blind Trial of Aripiprazole vs Perphenazine in Schizophrenia and Comorbid Cocaine Dependence.

Beresford T, Buchanan J, Thumm EB, Emrick C, Weitzenkamp D, Ronan PJ.

J Clin Psychopharmacol. 2017 Dec;37(6):657-663. doi: 10.1097/JCP.0000000000000789.

PMID:
28984746
7.

Case 5: A 7-year-old Autistic Boy with Altered Movements and Mental Status.

Fatima S, Mottola N.

Pediatr Rev. 2017 Oct;38(10):493. doi: 10.1542/pir.2017-0044. No abstract available.

PMID:
28972055
8.

Neuroleptic malignant syndrome with thyroid disorder: An unusual case report.

Zhang F, Kanzali P, Rubin V, Paras C, Goldman J.

Medicine (Baltimore). 2017 Sep;96(39):e8191. doi: 10.1097/MD.0000000000008191.

9.

An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan.

Ichikawa H, Hiratani M, Yasuhara A, Tsujii N, Oshimo T, Ono H, Tadori Y.

Psychiatry Clin Neurosci. 2018 Feb;72(2):84-94. doi: 10.1111/pcn.12607. Epub 2017 Nov 8.

PMID:
28941259
10.

Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.

McEvoy JP, Risinger R, Mykhnyak S, Du Y, Liu CC, Stanford AD, Weiden PJ.

J Clin Psychiatry. 2017 Sep/Oct;78(8):1103-1109. doi: 10.4088/JCP.17m11625.

11.

Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre.

Christensen AP, Boegevig S, Christensen MB, Petersen KM, Dalhoff KP, Petersen TS.

Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):293-298. doi: 10.1111/bcpt.12902. Epub 2017 Oct 11.

PMID:
28881461
12.

Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.

Correll CU, Kohegyi E, Zhao C, Baker RA, McQuade R, Salzman PM, Sanchez R, Nyilas M, Carson W.

J Am Acad Child Adolesc Psychiatry. 2017 Sep;56(9):784-792. doi: 10.1016/j.jaac.2017.06.013. Epub 2017 Jul 8.

PMID:
28838583
13.

TSH and PRL, side-effect markers in aripiprazole treatment: adjunctive aripiprazole-induced thyrotropin oversuppression in a young man with schizophrenia.

Ohta H, Inoue S, Hara K, Watanabe A.

BMJ Case Rep. 2017 Aug 22;2017. pii: bcr-2017-220192. doi: 10.1136/bcr-2017-220192.

PMID:
28830897
14.

Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study.

Pringsheim T, Ho J, Sarna JR, Hammer T, Patten S.

J Clin Psychopharmacol. 2017 Oct;37(5):498-504. doi: 10.1097/JCP.0000000000000760.

PMID:
28816926
15.

Delirium in hospitalized patients: Risks and benefits of antipsychotics.

Thom RP, Mock CK, Teslyar P.

Cleve Clin J Med. 2017 Aug;84(8):616-622. doi: 10.3949/ccjm.84a.16077. Review.

16.

Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?

Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, Garcia M, Aguirre C.

Int Clin Psychopharmacol. 2018 Jan;33(1):56-58. doi: 10.1097/YIC.0000000000000194.

PMID:
28777129
17.

Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.

Cameron C, Zummo J, Desai DN, Drake C, Hutton B, Kotb A, Weiden PJ.

Value Health. 2017 Jul - Aug;20(7):876-885. doi: 10.1016/j.jval.2017.03.010. Epub 2017 May 9. Review.

18.

[Tardive movement disorders with antipsychotics – a case of aripirazole-induced tardive dystonia and review of the literature].

Pitzer M, Engelmann G, Stammschulte T.

Z Kinder Jugendpsychiatr Psychother. 2017 Jul;45(4):325-334. doi: 10.1024/1422-4917/a000460. Epub 2016 Sep 26. German.

PMID:
28682214
19.

Antipsychotic-associated psoriatic rash - a case report.

Bujor CE, Vang T, Nielsen J, Schjerning O.

BMC Psychiatry. 2017 Jul 4;17(1):242. doi: 10.1186/s12888-017-1411-2.

20.

Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database.

Sakai T, Ohtsu F, Mori C, Tanabe K, Goto N.

Drug Saf. 2017 Nov;40(11):1141-1146. doi: 10.1007/s40264-017-0560-z.

PMID:
28664356

Supplemental Content

Loading ...
Support Center